AGIO · Agios Pharmaceuticals, Inc.
$35.97
-1.00 (-2.70%)
At close · Jul 28
Market Cap
$2.14B
Shares
59.47M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-18 | — | |
| 8-K | 2026-04-29 | — | |
| 10-Q | 2026-04-29 | 2026-03-31 | |
| DEF 14A | 2026-04-24 | 2026-06-18 | |
| 10-K | 2026-02-12 | 2025-12-31 | |
| 8-K | 2026-02-12 | — | |
| 8-K | 2026-01-12 | — | |
| 8-K | 2025-10-30 | — | |
| 10-Q | 2025-10-30 | 2025-09-30 | |
| 8-K | 2025-08-04 | — | |
| 10-Q | 2025-07-31 | 2025-06-30 | |
| 8-K | 2025-07-31 | — | |
| 8-K | 2025-07-08 | 2025-07-03 | |
| 8-K | 2025-06-18 | — | |
| 8-K | 2025-05-01 | — | |
| 10-Q | 2025-05-01 | 2025-03-31 | |
| DEF 14A | 2025-04-25 | 2025-06-18 | |
| 10-K | 2025-02-13 | 2024-12-31 | |
| 8-K | 2025-02-13 | — | |
| 8-K | 2025-02-13 | 2025-02-10 | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2025-01-06 | 2025-01-03 | |
| 10-Q | 2024-10-31 | 2024-09-30 | |
| 8-K | 2024-10-31 | — | |
| 8-K | 2024-08-01 | — | |
| 10-Q | 2024-08-01 | 2024-06-30 | |
| 8-K | 2024-06-20 | — | |
| 8-K | 2024-05-28 | 2024-05-24 | |
| 10-Q | 2024-05-02 | 2024-03-31 | |
| 8-K | 2024-05-02 | — | |
| DEF 14A | 2024-04-26 | 2024-06-20 | |
| 8-K | 2024-02-15 | — | |
| 10-K | 2024-02-15 | 2023-12-31 | |
| 8-K | 2024-01-08 | — | |
| 10-Q | 2023-11-02 | 2023-09-30 | |
| 8-K | 2023-11-02 | — | |
| 10-Q | 2023-08-03 | 2023-06-30 | |
| 8-K | 2023-08-03 | — | |
| 8-K | 2023-06-14 | 2023-06-13 | |
| 8-K | 2023-05-25 | 2023-05-22 | |
| 8-K | 2023-05-04 | — | |
| 10-Q | 2023-05-04 | 2023-03-31 | |
| DEF 14A | 2023-04-26 | 0001-01-01 | |
| 8-K | 2023-04-19 | 2023-04-17 | |
| 8-K | 2023-03-03 | 2023-03-02 | |
| 8-K | 2023-02-23 | — | |
| 10-K | 2023-02-23 | 2022-12-31 | |
| 8-K | 2023-01-09 | 2023-01-08 | |
| 8-K | 2022-12-16 | 2022-12-12 | |
| 8-K | 2022-12-06 | 2022-12-05 |
Showing 1–50 of 111 filings
Key facts
CIK
1439222
CUSIP
00847X104
13F (30d)
61 filings
37 filers
Visit website
Investor relations